JAGX stock news · Jaguar Health
Get alerts for JAGX
Follow Jaguar Health (JAGX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for JAGX12 health care stocks changed a lot in prices during Friday's after-hours trading.
NeutralJaguar Health shares fell 6.1% in Friday's after-market session. The roundup gives no business news that changes its outlook.
12 health care stocks are changing a lot during Friday's trading.
NeutralJaguar Health shares fell 19.4% to $3.70, but the article gives no business news behind the move. It does not change the company's outlook.
12 health care stocks are changing a lot before the market opens on Friday.
NeutralJaguar Health shares fell 29.85%. The article gives no company news, so this does not change its business outlook.
12 health care companies saw big price changes during Tuesday's trading.
NeutralJaguar Health shares rose about 23% during Tuesday's session. The article gives no company news explaining the move, so it does not change the company's outlook.
12 health care stocks are changing in price before the market opens on Tuesday.
NeutralJaguar Health's shares rose about 34% before Tuesday's market opened. The article reports no company news, so it does not change the business outlook.
Jaguar Health (JAGX) shares jumped more than 34% after hours. What happened?
NeutralJaguar Health delayed royalty payments and its $6.22 million loan maturity until Jan. 1, 2027, but still owes them. Its share dividend changes share count, not reported business results.
12 health care stocks are changing a lot during Monday's trading.
NeutralJaguar Health shares rose 33.6% during Monday’s session, but the story gives no reason or company update. The price move alone does not change its business outlook.
12 health care companies saw big changes during Monday's trading.
NeutralJaguar Health's shares rose 34% on Monday. The story gives no company news to show that its business prospects changed.
12 health care companies are changing in price before the market opens on Monday.
NeutralJaguar Health shares rose 15.84% before Monday's open, but the story gives no company news explaining the move. It does not change the picture of Jaguar Health's business.
Jaguar Health, Inc. has signed an important agreement.
NeutralJaguar Health reported issuing shares under a note-exchange agreement. The filing gives no share count or debt change, so it does not establish a change in JAGX's outlook.
12 health care stocks changed a lot in Wednesday's after-hours trading.
NeutralJaguar Health's stock fell about 8.5% to $8.15, but the article gives no company updates, so this does not change the company's outlook.
The Dow dropped 100 points, but General Mills shared good news about its first-quarter profits.
Bad for JAGXJaguar Health shares fell 51% to $16.93, a large decline that outweighs the prior-day jump tied to an FDA fee-waiver mention in this report.
12 health care companies are changing prices before the market opens on Wednesday.
NeutralJaguar Health shares fell 47.9% pre-market to $17.95, yet the article only lists the decline and provides no explanation affecting the business view.
On Tuesday, 12 health care stocks changed a lot, with Jaguar Health jumping 304.5% and Silexion Therapeutics dropping 3%.
NeutralThe article reports a big intraday jump in Jaguar Health shares, but no company news is given, so the report does not change how we read Jaguar Health.
Jaguar Health, Inc. is changing the rights of its shareholders after a one-for-fifteen stock split starting September 17, 2026.
NeutralJaguar Health announced a 1-for-15 reverse stock split effective Sept 17, 2026. It changes share counts but not company operations, so it does not change our view.
On Tuesday, 12 health care stocks saw big price changes during the day.
Bad for JAGXJaguar Health decreased 24.2% to $0.45, a large drop that points to weaker investor interest.
Q2 2026 results delivered by Jaguar Health: Complete earnings call transcript available.
NeutralJaguar Health's Q2 2026 results reveal a strategic pivot towards rare disease treatments, particularly with crofelemer, and a lucrative licensing deal that could bolster future revenues. Despite a decrease in net revenue, the company's focus on non-dilutive funding and promising clinical trial results may attract investor interest.